This could also explain why NCAPH levels are not associated with the poor prognosis of breast tumours that do not express ER, such as HER2‐enriched and basal tumours, as well as the participation of NCAPH in the poor clinical outcome of other hormone‐dependent tumours, such as ovarian, endometrial, cervical and possibly prostate cancers.81, 82, 83, 84, 85, 86. This evidence concerns the gene ERBB2 and prostate cancer.